NASDAQ · Biotechnology

TVRD (TVRD) Stock

$2.14 -12.30% NASDAQ: TVRD Healthcare

Valuation

MetricValue
Price$2.14
Market Cap$20.08M
P/E Ratio-1.21
P/B Ratio1.77
P/S Ratio0.00
EPS (TTM)$-3.26
52-Week High$43.65
52-Week Low$1.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-85.71%
ROA-56.25%
ROCE-128.57%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio2.91

Annual Financials (USD)

Metric20212022202320242025
Revenue$23.0M$42.0M$21.0M$7.0M$0
Operating Profit$-89.0M$-88.0M$-121.0M$-56.0M$-27.0M
Net Profit$-88.0M$-85.0M$-119.0M$-71.0M$-18.0M
EPS$-62.77$-2.20$-1.85$-46.59$-3.26
Op Margin-386.9%-209.1%-579.4%-781.6%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$247.0M$45.0M$27.0M$44.0M$32.0M
Total Liabilities$20.0M$90.0M$89.0M$48.0M$11.0M
Cash$13.0M$21.0M$23.0M$38.0M$21.0M
Borrowings$4.0M$2.0M$0$44.0M$0

Latest News

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know Zacks · Jul 9, 2026 Piper Sandler Upgrades Tvardi Therapeutics to Overweight From Neutral, Adjusts Price Target to $13 From $3 MT Newswires · Jul 9, 2026 Sector Update: Healthcare Stocks Lower Wednesday Afternoon MT Newswires · Jul 8, 2026 Top Midday Gainers MT Newswires · Jul 8, 2026 Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement GlobeNewswire · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-60.0M$-18.0M$-21.0M$-61.0M$-23.0M
Investing Cash Flow$-5.0M$-22.0M$20.0M$48.0M$-10.0M
Financing Cash Flow$0$0$-36.0M$0$22.0M
Net Cash Flow$-18.0M$-40.0M$1.0M$-14.0M$-11.0M
Free Cash Flow$-60.0M$-18.0M$-21.0M$-62.0M$-23.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-62.62%
Quick Ratio2.25
Interest Coverage—
Return 1Y-88.55%
Return 3Y-97.10%
Return 5Y-99.36%

Ownership

Insiders Held26.02%
Institutions Held22.35%
Institutions Float Held30.21%
Institutional HolderSharesReport Date
Slate Path Capital, LP704,1182026-03-31
Blackrock Inc.388,0752026-03-31
Vanguard Capital Management LLC344,7082026-03-31
American Financial Group Inc.223,6592026-03-31
Geode Capital Management, LLC182,3392026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
CALCCalciMedica, Inc. $0.73 -3.82% -0.57 $11.55M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
LTRN $2.63 -0.75% -2.02 $33.56M 0.00%

About TVRD

TVRD is led by CEO Imran Alibhai, employs 17 people, headquartered in US, publicly traded since 2025.

TVRD stock trades at $2.14 with a market capitalization of $20.08M. The stock is valued at a price-to-earnings (P/E) ratio of -1.21, price-to-book of 1.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.50 and $43.65, and currently trades 95.1% below its 52-week high.

On profitability, TVRD generates a return on equity (ROE) of -85.71%, return on capital employed of -128.57%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides